Journal of cardiovascular pharmacology and therapeutics
-
J. Cardiovasc. Pharmacol. Ther. · Apr 2002
Clinical Trial Controlled Clinical TrialEffects of diltiazem and esmolol on cycle length and spontaneous conversion of atrial fibrillation.
Calcium channel blocking agents have been shown to prolong the duration of atrial fibrillation. This study compared the effects of intravenous diltiazem and esmolol on the cycle length and conversion rate of pacing-induced atrial fibrillation. ⋯ Intravenous diltiazem shortens the atrial fibrillation cycle length and lowers the probability of spontaneous conversion of recent-onset atrial fibrillation to sinus rhythm. These results suggest that the use of diltiazem for acute rate control may unwittingly prolong the duration of recent-onset atrial fibrillation.
-
J. Cardiovasc. Pharmacol. Ther. · Apr 2002
ReviewSpontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride.
Adverse cardiac events, typically long QT syndrome, have been reported in patients treated with the gastrointestinal prokinetic agent cisapride. ⋯ In most cases with high or medium confidence in the diagnosis of cisapride-associated long QT syndrome, recognized cofactors for long QT syndrome were present. The risk of cisapride-related long QT syndrome may be minimized by avoiding cofactors.